Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients
Our results show a dose-response relationship between both CRP levels and AES with immuno-metabolic risk biomarkers, indicating that CRP and AES combined can capture immuno-metabolic features of MDD. Combining these available and scalable indexes may be an effective strategy to select a patient sample with immuno-metabolic dysregulation who may benefit from treatments targeting inflammatory or metabolic pathways.
Authors
- Erik J. Giltay (ORCID: https://orcid.org/0000-0001-8874-2292)
- J.C. Zwiep (ORCID: https://orcid.org/0000-0001-9744-8298)
- Y. Milaneschi
- F. Lamers
- Brenda W.J.H. Penninx (ORCID: https://orcid.org/0000-0001-7779-9672)
- C H Vinkers
Institutions
- Leiden University Medical Center (NL)
- Amsterdam Neuroscience (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Brain Behavior and Immunity
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1016/j.bbi.2024.11.033
- Citations
- 15
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.36
Funders
- Amsterdam University Medical Centers
- Universiteit Leiden
- Rijksuniversiteit Groningen
- ZonMw
- GGZ inGeest
- GGZ Friesland
- GGZ Drenthe
- Leids Universitair Medisch Centrum
- Universitair Medisch Centrum Groningen
- Hersenstichting
- Amsterdam Neuroscience